Literature DB >> 9622670

Hydrolysis of the neuropeptide N-acetylaspartylglutamate (NAAG) by cloned human glutamate carboxypeptidase II.

R Luthi-Carter1, A K Barczak, H Speno, J T Coyle.   

Abstract

Glutamate carboxypeptidase II may modulate excitatory neurotransmission through the catabolism of the neuropeptide N-acetylaspartylglutamate (NAAG) and possibly other endogenous peptide substrates. To investigate the molecular properties of cloned human GCP II (hGCP II), we analyzed the NAAG-hydrolytic activity conveyed by transfection of a full-length hGCP II cDNA into PC3 cells, which do not express GCP II endogenously. Membrane fractions from these cells demonstrated activity with an apparent Km of 73 nM and Vmax of 35 pmol/(mg protein*min). Activity was inhibited by EDTA and stimulated by the addition of CoCl2. Addition of GCP II inhibitors beta-NAAG, quisqualic acid and 2-(phosphonomethyl)pentanedioic acid (PMPA) inhibited hydrolysis of 2.5 nM NAAG with IC50s of 201 nM, 155 nM and 98 pM, respectively. In competition experiments designed to infer aspects of hGCP II substrate selectivity, NAAG was the most potent alpha peptide tested, with an IC50 of 26 nM. Folate derivatives and some other gamma-glutamyl peptides showed comparable affinity to that of NAAG, also displaying IC50s in the low nM range. Taken together with previous evidence demonstrating their presence in GCP II-expressing tissues, these data suggest that both NAAG and folates are good candidate substrates for GCP II in vivo. Copyright 1998 Elsevier Science B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9622670     DOI: 10.1016/s0006-8993(98)00244-3

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  16 in total

1.  Glutamate carboxypeptidase II and folate deficiencies result in reciprocal protection against cognitive and social deficits in mice: implications for neurodevelopmental disorders.

Authors:  Laura R Schaevitz; Jonathan D Picker; Jasmine Rana; Nancy H Kolodny; Barry Shane; Joanne E Berger-Sweeney; Joseph T Coyle
Journal:  Dev Neurobiol       Date:  2012-06       Impact factor: 3.964

Review 2.  Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer.

Authors:  C Bařinka; C Rojas; B Slusher; M Pomper
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

3.  Structural and biochemical characterization of the folyl-poly-γ-l-glutamate hydrolyzing activity of human glutamate carboxypeptidase II.

Authors:  Michal Navrátil; Jakub Ptáček; Pavel Šácha; Jana Starková; Jacek Lubkowski; Cyril Bařinka; Jan Konvalinka
Journal:  FEBS J       Date:  2014-06-17       Impact factor: 5.542

Review 4.  Sensorimotor gating deficits in "two-hit" models of schizophrenia risk factors.

Authors:  Asma Khan; Susan B Powell
Journal:  Schizophr Res       Date:  2017-10-22       Impact factor: 4.939

Review 5.  Looking for Drugs in All the Wrong Places: Use of GCPII Inhibitors Outside the Brain.

Authors:  James J Vornov; Diane Peters; Mike Nedelcovych; Kristen Hollinger; Rana Rais; Barbara S Slusher
Journal:  Neurochem Res       Date:  2019-11-20       Impact factor: 3.996

6.  Substrate specificity of prostate-specific membrane antigen.

Authors:  Marc O Anderson; Lisa Y Wu; Nicholas M Santiago; Jamie M Moser; Jennifer A Rowley; Erin S D Bolstad; Clifford E Berkman
Journal:  Bioorg Med Chem       Date:  2007-08-11       Impact factor: 3.641

Review 7.  The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease.

Authors:  James C Evans; Meenakshi Malhotra; John F Cryan; Caitriona M O'Driscoll
Journal:  Br J Pharmacol       Date:  2016-09-23       Impact factor: 8.739

8.  Structural basis of interactions between human glutamate carboxypeptidase II and its substrate analogs.

Authors:  Cyril Barinka; Klara Hlouchova; Miroslava Rovenska; Pavel Majer; Miroslawa Dauter; Niyada Hin; Yao-Sen Ko; Takashi Tsukamoto; Barbara S Slusher; Jan Konvalinka; Jacek Lubkowski
Journal:  J Mol Biol       Date:  2008-01-05       Impact factor: 5.469

9.  Phencyclidine and dizocilpine induced behaviors reduced by N-acetylaspartylglutamate peptidase inhibition via metabotropic glutamate receptors.

Authors:  Rafal T Olszewski; Marta M Wegorzewska; Ana C Monteiro; Kristyn A Krolikowski; Jia Zhou; Alan P Kozikowski; Katrice Long; John Mastropaolo; Stephen I Deutsch; Joseph H Neale
Journal:  Biol Psychiatry       Date:  2007-06-27       Impact factor: 13.382

10.  NAAG peptidase inhibitor improves motor function and reduces cognitive dysfunction in a model of TBI with secondary hypoxia.

Authors:  Gene G Gurkoff; Jun-Feng Feng; Ken C Van; Ali Izadi; Rahil Ghiasvand; Kiarash Shahlaie; Minsoo Song; David A Lowe; Jia Zhou; Bruce G Lyeth
Journal:  Brain Res       Date:  2013-04-03       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.